<DOC>
	<DOCNO>NCT01910883</DOCNO>
	<brief_summary>This first time finafloxacin administer human intravenously . The principal aim study obtain safety tolerability data finafloxacin administer intravenously single multiple dos healthy subject .</brief_summary>
	<brief_title>Safety Tolerability Single Multiple Intravenous Doses Finafloxacin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Subjects male female ethnic origin 18 65 year age body mass index ( BMI ) 18.0 32.0 kg/m2 inclusive . Female subject must nonchildbearing potential , defined follow : Female subject 50 year age less must surgically sterile postmenopausal ( define least two year post cessation menses and/or follicular stimulate hormone &gt; 40 mIU/mL serum oestradiol &lt; 110 pmol/L ) . Female subject 51 year age must surgically sterile postmenopausal ( define value follicular stimulate hormone &gt; 40 mIU/mL spontaneous menstruation least one year first dose ) . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation . Subjects give write informed consent participate study abide study restriction . Male subject willing , whose partner willing , use appropriate contraception ( condom spermicidal foam/gel/film/cream/suppository ) time first dose 3 month final dosing occasion . Subjects receive prescribed systemic topical medication within 14 day ( corticosteroid within 4 week ) first dose administration ( female subject , stable hormone replacement therapy acceptable ) unless opinion Investigator medication interfere study procedure compromise safety . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration ( exception vitamin/mineral supplement ) unless opinion Investigator medication interfere study procedure compromise safety . Subjects received medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug past 3 month . Subjects donate blood , plasma platelet 3 month prior randomisation make donation two occasion within 12 month precede first dose administration . Subjects significant history drug allergy determine Investigator . Subjects current history allergy antibiotic determine Investigator . Subjects range value Liver Function Tests . Subjects nonhaemolytic bilirubinaemia ( Gilbert 's syndrome ) . Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator . Subjects supine blood pressure supine pulse rate high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 40 bpm , respectively , confirm repeat assessment . Subjects consume 28 unit ( male ) 21 unit ( female ) alcohol per week significant history alcoholism drug/chemical abuse determine Investigator ( 1 unit alcohol equal Â½ pint [ 285 mL ] beer lager , 1 glass [ 125 mL ] wine , 1/6 gill [ 25 mL ] spirit ) . Subjects positive urine drug screen alcohol breath test result screen first admission . Subjects smoke 10 cigarette equivalent tobacco per day . Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological major disorder determine Investigator . Subjects history tendon rupture tendonitis . Subjects clinically significant illness within 4 week start dose administration determine Investigator . 19 . Subjects know serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test HIV antibody . Subjects abnormality 12lead ECG , opinion investigator , increase risk participate study , QTcB interval &gt; 450 msec ( male ) great 470 msec ( female ) , 2nd 3rd degree Atrioventricular block , complete leave bundle branch block , complete right bundle branch block WolffParkinsonWhite Syndrome , define PR &lt; 110 msec , confirm repeat ECG . Subjects previously take part withdrawn study . Subjects , opinion Investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>